The discovery cohort study, which consisted of recipient and donor pairs for which the HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were completely matched, revealed that the donor G/G genotype at rs11536889 (+3725G>C) of the TLR4 gene predicts significantly better 5-year PFS than other genotypes in patients with hematological malignancies receiving unrelated BMT. This evidence concerns the gene TLR4 and hematologic disorder.